tbuckley/cabot-search huggingface dataset:
Abstract 3820: Expression of ST6Gal-1 in colorectal cancer and patient prognosis
Authors: Trafina Jadhav, Saksham Narang, Jeehyun Bae, Matthew Schultz, Isam-Eldin Eltoum, Susan Bellis, Sejong Bae, Upender Manne
Journal: Cancer Research (2014)

Abstract Background: ST6Gal-1 sialyltransferase, a type II membrane protein that catalyzes the transfer of sialic acid to the N-glycans of certain receptors, is upregulated in several cancers, including colorectal cancers (CRCs), and its levels correlate with metastatic potential. Therefore, we investigated its prognostic value in CRCs. Methodology: Formalin-fixed, paraffin-embedded CRC tissues from African Americans (Blacks) (n=50) and non-Hispanic Caucasians (Whites) (n=51) patients were evaluated for immunohistochemical (IHC) expression of ST6Gal-1. IHC expression was assessed using an anti-human ST6Gal-1 polyclonal antibody (R&amp;D Systems) with antigen retrieval. The antibody-antigen complex was detected by the Immpact NovaRed system (Vector Labs). A semiquantitative immunostaining scoring system (ISS) on a scale of 0-4 was developed to assess the ST6Gal-1 expression, and a cutoff value (1.2 ISS) was determined by the bootstrap method. This value was used to classify tumors as low- or high-ST6Gal-I expressors. Previously, these tissues were evaluated for p53 nuclear accumulation (p53nac), an indicator of abnormal p53, by IHC. ST6Gal-1 expression levels were correlated with demographic and clinicopathologic features and with patient survival. Results: Increased ST6Gal-1 expression was observed in all CRCs as compared to their corresponding normal tissues. The overall frequency of CRCs with increased ST6Gal-1 expression was 80%; it was more commonly found in Blacks (88%, 44 of 50) than in Whites (70%, 36 of 51) (X2 p=0.031). Also, increased expression was associated with p53nac, and ST6Gal-1 expression was higher in CRCs that exhibited p53nac (87%, 42 of 48) relative to CRCs without p53nac (70%, 35 of 50) (X2 p = 0.034). Moreover, patients with CRCs with high ST6Gal-1 had lower median survival (29.3 months) relative to those with low ST6Gal-1 expression (58.5 months). Conclusions: These preliminary findings suggest that increased expression of ST6Gal-1 expression, found predominantly in Blacks patients and in CRCs with abnormal p53, is associated with poor patient survival. Citation Format: Trafina Jadhav, Saksham Narang, Jeehyun Bae, Matthew Schultz, Isam-Eldin Eltoum, Susan Bellis, Sejong Bae, Upender Manne. Expression of ST6Gal-1 in colorectal cancer and patient prognosis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3820. doi:10.1158/1538-7445.AM2014-3820
Carbon Monoxide Poisoning
Authors: Armin Ernst, Joseph D. Zibrak
Journal: New England Journal of Medicine (1998)

Carbon monoxide intoxication continues to be one of the most common causes of morbidity due to poisoning in the United States.1,2 It may be intentional or accidental, and exposure may be lethal. Approximately 600 accidental deaths due to carbon monoxide poisoning are reported annually in the United States,3 and the number of intentional carbon monoxide–related deaths is 5 to 10 times higher.1 The rate of accidental death caused by carbon monoxide from motor vehicles is higher in the northern United States and peaks during the winter months.4 The intentional deaths occur year-round without significant peaks.1 The severe winter of . . .
Abstract 17132: E258K HCM-Causing Mutation in Myosin Binding Protein-C Accelerates Contractile Kinetics in Non-Hypertrophied Engineered Cardiac Tissue
Authors: Willem J De Lange, Richard L Moss, John C Ralphe
Journal: Circulation (2010)

Mutations in the cardiac myosin binding protein C gene (MYBPC3) are common causes of hypertrophic cardiomyopathy (HCM) in humans. Even though the MYBPC3 E258K missense mutation is among the most pr...
cIAP1 Localizes to the Nuclear Compartment and Modulates the Cell Cycle
Authors: Temesgen Samuel, Kazuya Okada, Marc Hyer, Kate Welsh, Juan M. Zapata, John C. Reed
Journal: Cancer Research (2005)

Abstract We explored the location and function of the human cIAP1 protein, a member of the inhibitor of apoptosis protein (IAP) family. Unlike family member X-linked IAP (XIAP), which was predominantly cytoplasmic, the cIAP1 protein localized almost exclusively to nuclei in cells, as determined by immunofluorescence microscopy and subcellular fractionation methods. Interestingly, apoptotic stimuli induced nuclear export of cIAP1, which was blocked by a chemical caspase inhibitor. In dividing cells, cIAP1 was released into the cytosol early in mitosis, then reaccumulated in nuclei in late anaphase and in telophase, with the exception of a pool of cIAP1 that associated with the midbody. Survivin, another IAP family member, and cIAP1 were both localized on midbody microtubules at telophase, and also interacted with each other during mitosis. Cells stably overexpressing cIAP1 accumulated in G2-M phase and grew slower than control-transfected cells. These cIAP1-overexpressing cells also exhibited cytokinesis defects over 10 times more often than control cells and displayed a mitotic checkpoint abnormality with production of polyploid cells when exposed to microtubule-targeting drugs nocodazole and paclitaxel (Taxol). Our findings demonstrate a role for overexpressed cIAP1 in genetic instability, possibly by interfering with mitotic functions of Survivin. These findings may have important implications for cancers in which cIAP1 overexpression occurs.
Mummy Mask of a Noblewoman
Authors: Sidney Goldstein
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Non-human immunodeficiency virus Kaposi's sarcoma can be effectively treated with low-dose interferon-α despite the persistence of herpesvirus-8
Authors: None Deichmann, None Thome, None JÄckel, None Utermann, None Bock, None Waldmann, None NÄher
Journal: British Journal of Dermatology (1998)

Three patients, negative for human immunodeficiency virus (HIV), with histologically and polymerase chain reaction-proven non-HIV Kaposi's sarcoma who received low-dose interferon (IFN) as first-line treatment because of disseminated symptomatic disease are reported. Applying 3-18 million IU of IFN-alpha 2a per day, 3 days a week, subcutaneously for 8-20 months, major responses were achieved in all three cases. Tumour regression was observed within 4 months and has continued for 57 and 18 months to date (cases 1 and 2, respectively). Influenza-like symptoms, including fever, headaches and fatigue, were mild side-effects. However, in the third patient interferon injections had to be stopped because of hepatic enzyme elevation. Including this case report, 27 non-HIV Kaposi's sarcoma patients subcutaneously treated with IFN-alpha have been reported in literature. Most therapy regimens included 3-18 million IU IFN-alpha per day for 3 days a week. Twenty of 27 patients, or 74%, responded to therapy, whereas seven patients or 26% had stable or progressive disease. Relapse after IFN withdrawal can occur but is frequently delayed and limited, as in case 1. Following the response to IFN treatment, human herpesvirus-8 DNA was detected in the blood mononuclear cells of all three patients, possibly contributing to future relapses.
Reducing Preterm Delivery
Authors: Joan Stephenson
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A homeobox gene, HLXB9, is the major locus for dominantly inherited sacral agenesis
Authors: Alison J. Ross, Victor Ruiz-Perez, Yiming Wang, Donna-Marie Hagan, Steve Scherer, Sally A. Lynch, Susan Lindsay, Emily Custard, Elena Belloni, David I. Wilson, Roy Wadey, Frances Goodman, Karen Helene Orstavik, Tom Monclair, Steve Robson, William Reardon, John Burn, Pete Scambler, Tom Strachan.
Journal: Nature Genetics (1998)
Abstract 15848: Restoration of Normal Cardiomyocyte Basal and β-Adrenergic Receptor (AR) Subtype Modulation in Heart Failure by Chronic Phosphodiesterase Type 5 Inhibition With Sildenafil
Authors: Tiankai Li, Heng-Jie Cheng, Shadi A Qasem, Michael Callahan, Wei-Min Li, Che Ping Cheng
Journal: Circulation (2014)

Background: We have shown that Sildenafil (SIL), a selective PDE5 inhibitor reversed left ventricular (LV) dysfunction and β- adrenergic receptors (AR) desensitization in heart failure (HF). However the mechanism is not yet clear. Recent evidence suggests that normal myocardial performance depend on the balance in cardiomyocyte β 3 -, β 1 -, and β 2 -AR. Pivotal restructuring of β-AR system resulting in decline of β-adrenergic reserve plays a crucial role in the development of HF. We assessed the hypothesis that chronic SIL would prevent HF-induced abnormalities of β-AR subtype-stimulated regulation on intrinsic LV myocyte function and [Ca 2+ ] i regulation, thus restoring cardiac function. Methods: Studies were conducted in 3 groups (10/group) of rats: 1) HF, 12 weeks (W) after receiving isoproterenol (ISO) (170 mg/kg sq for 2 days); 2) HF/SIL, 8W after receiving ISO, SIL (70 μg/kg/day sq via mini pump) was initiated and given for 1 M; and 3) controls. After 12W, we compared LV myocyte contractile and [Ca 2+ ] iT responses to β-AR subtype stimulation by random exposure of myocytes to ISO (10 -8 M) or a selective β 1 -, β 2 -, or β 3 -agonist, Norepinephrine (NE, 10 -7 M), Zinterol (ZIN, 10 -5 M) and BRL-37,344 (BRL, 10 -8 M), respectively, during drug superfusion. Results: Only ISO-treated rats had HF showed 46% decreased LV contractility (E ES ) and extensive LV myocardium fibrosis. Compared with normal myocytes (N), in HF myocytes, basal cell contractility (dL/dt max , HF: 77 vs N: 136 μm/s), relaxation and [Ca 2+ ] iT all significantly decreased. ISO-stimulated dL/dt max (31% vs 67%) was attenuated accompanied by a diminished NE-mediated increase in dL/dt max (13% vs 49%), but enhanced BRL-induced decreases in dL/dt max (-29% vs -16%).The response of dL/dt max (25% vs 15%) to ZIN was increased. Importantly, in HF/SIL myocytes, the basal dL/dt max (139 μm/s) and [Ca 2+ ] iT remained close to control values with preserved β-stimulated positive modulation on cell contraction. The increases in dL/dt max in response to ISO (70%) and NE (44%) were similar as in normal myocytes, but repose to ZIN (27%) was enhanced. Conclusions: Chronic SIL reverses β-adrenergic signaling defects, resensitizing the β-AR subtype system modulation on LV myocytes function, thus playing a salutary role in HF.
Abstract P446: External Validation Of The CAMUNI Score, A Long-term Cvd Prediction Equation For Low-incidence Populations.
Authors: Giovanni Veronesi, Chiara Donfrancesco, Lloyd E Chambless, Francesco Gianfagna, Luigi Palmieri, Giuseppe Mancia, Giancarlo Cesana, Simona Giampaoli, Marco M Ferrario
Journal: Circulation (2014)

Aims: We assess the external validation, on a “new” set of subjects, of the CAMUNI 20-year risk score, developed in a northern Italian population. Although an external validation analysis is recommended before adopting a score in clinical practice, it is rarely performed in long-term prediction equations as it requires similar long-term follow-up procedures in different cohort studies. Methods: The CAMUNI risk score was developed to estimate the 20-year risk of first coronary or ischemic stroke event, fatal or non-fatal, in 5247 (2574 men) 35-69 subjects free of CVD at baseline enrolled in late 1980s-early 1990s in Brianza, northern Italy (derivation set). The score is based on two gender-specific Cox models, including age, total- and HDL-cholesterol, systolic blood pressure, anti-hypertensive treatment, cigarette smoking and diabetes. As validation set, we considered 5307 (2418 men) subjects enrolled in the Rome area in the same time span (MATISS Study). Both the derivation and the validation cohorts shared the same procedures for baseline risk assessment and follow-up procedures, including MONICA definition of acute events. We evaluated the performance of the CAMUNI score in the validation set; the Framingham CVD risk score was used for comparison. The absolute predicted risk from both scores was re-calibrated to the 20-year risk observed in the validation set. We report the calibration slope as a measure of calibration; a value different from 1 is suggestive of a different strength in predictor effects. The Area Under the ROC-curve (AUC) measured the discrimination ability; the AUC in the validation set was compared to the value in the derivation set, corrected for over-optimism. Results: The 20-year Kaplan-Meier risk of event was 16.1% (derivation set; 315 events) and 13.2% (validation set; 238 events) in men, and 6.1% (123 events) and 5.6% (119 events) in women. The calibration slope for the CAMUNI score did not significantly differ from 1 in men (1.1; 95% confidence interval 0.9; 1.2) nor in women (1.0; 0.8;1.2). The Framingham score performed equally well in men (1.1; 0.9; 1.2) but worse in women (1.3; 1.1;1.6). In the derivation set, the over-optimism corrected AUC for the CAMUNI model was 0.737 (men) and 0.801 (women); the corresponding figures in the validation set were 0.732 (95% CI: 0.727-0.738) in men, and 0.801 (0.794-0.808) in women. The Framingham score performed less well in men (0.722; 0.717-0.727) and in women (0.705; 0.699-0.711). Conclusions: Based on these preliminary results, the CAMUNI 20-year risk score seems to be appropriate for long-term risk prediction in Italy and, more generally, in low-incidence populations.
Action of Partially Thiolated Polynucleotides on the DNA Polymerase α from Regenerating Rat Liver
Authors: Mel-Ping Kung, Yau-kwan Ho, Thomas J. Bardos
Journal: Cancer Research (1976)

The effects of partially thiolated polynucleotides on the DNA polymerase α from regenerating rat liver were investigated. The enzyme was isolated from the nuclear fraction essentially according to the method of Baril et al. ; it was characterized as the α polymerase on the basis of its response to synthetic templates and its inhibition with N -ethylmaleimide. Although polycytidylic acid had no effect on the DNA polymerase α either as a template or as an inhibitor, partially thiolated polycytidylic acid (MPC) was found to be a potent inhibitor, its activity being directly related to its extent of thiolation (percentage of 5-mercaptocytidylate units in the polymer). In comparison, the DNA polymerase β which was purified from normal rat liver nuclear fraction, was much less sensitive to inhibition by MPC. Analysis of the inhibition of the α polymerase by the method of Lineweaver and Burk showed that the inhibitory action of MPC was competitively reversible with the DNA template, but the binding of the 7.2%-thiolated MPC to the enzyme was much stronger than that of the template (Ki/Km < 0.03). Polyuridylic acid as such showed some inhibitory activity which increased on partial thiolation, but the 8.4%-thiolated polyuridylic acid was less active than the 7.2% MPC. When MPC was annealed with polyinosinic acid, it lost 80% of its inhibitory activity in the double-stranded configuration. However, 1 to 2%-thiolated DNA isolates were significantly more potent inhibitors than were comparable (1.2%-thiolated) MPC and showed competitive reversibility with the unmodified (but “activated”) DNA template. These results indicate that the inhibitory activities of partially thiolated polynucleotides depend not only on the percentage of 5-mercapto groups but also on the configuration, base composition, and other specific structural properties.
Anticoagulation? Antiplatelet? What's the Score?
Authors: Jonathan Hager
Journal: Annals of Internal Medicine (2015)

Letters4 August 2015Anticoagulation? Antiplatelet? What's the Score?Jonathan Hager, MDJonathan Hager, MDFrom Primary Care Internal Medicine, Rochester, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L15-5119 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Do Drs. Merli and Weitz (1) prescribe proton-pump inhibitors (PPIs) for all patients receiving triple therapy for the duration of their treatment? If so, they might want to mention this in their video. If not, why not?It would be nice to have actual percentages of absolute risks for stroke broken down by CHA2DS2-VASc (congestive heart failure/left ventricular dysfunction, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease, age 65 to 74 years, sex category) score rather than just the CHA2DS2-VASc score alone in this setting. For example, I believe that data from the SPAF ...Reference1. Merli GJ, Weitz HH. The consult guys—anticoagulation? Antiplatelet? What's the score? Ann Intern Med. 2015;162:CG1. [PMID: 25775340] doi:10.7326/G15-3003 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Primary Care Internal Medicine, Rochester, New York.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterest Forms.do?msNum=L15-0265. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Consult Guys - Anticoagulation? Antiplatelet? What's the Score? Geno J. Merli and Howard H. Weitz Anticoagulation? Antiplatelet? What's the Score? Geno J. Merli and Howard H. Weitz Anticoagulation? Antiplatelet? What's the Score? Geno J. Merli and Howard H. Weitz Metrics 4 August 2015Volume 163, Issue 3Page: 243KeywordsCardiovascular therapyConflicts of interestDiabetes mellitusDisclosureHemorrhageHypertensionIschemic strokePatient advocacyStrokeVascular diseases ePublished: 4 August 2015 Issue Published: 4 August 2015 CopyrightCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Abstract P338: Carotid Extra Media Thickness: An Indicator of Fat, Arterial Stiffness, Inflammation or Thickness?
Authors: Connie E McCoy, Philip R Khoury, Zhiqian Gao, Thomas R Kimball, Lawrence M Dolan, Elaine M Urbina
Journal: Circulation (2014)

Introduction: Epicardial fat is an emerging risk factor for cardiovascular (CV) disease. The importance of perivascular fat as a CV risk factor, which can be measured by ultrasound as Extra Medial Thickness (EMT), is less well described. Hypothesis: We hypothesized that EMT would be related to obesity and EMT may influence carotid stiffness. Methods: EMT defines the interface between the distal common carotid near wall to the jugular vein intima and includes arterial adventitia, interstitial tissue, perivascular fat, and vein intima. Mean of the maximum for right and left carotid EMT was measured at follow-up (5.9 years) with ultrasound (GE Vivid 7, Bothell, Wash.) in 112 subjects (34% male, 68% Non-Caucasian, mean age 22.9 ∓ 3.6 years) in a group of lean (L), obese (O), and T2DM (T) youth from a longitudinal study of CV Risk Factors. Anthropometrics, BP, fasting labs, and vascular measures for CIMT and arterial stiffness (Beta stiffness and Peterson’s elastic modulus) were obtained at baseline and follow-up. Variance stabilizing transformations were performed as appropriate. ANOVA was performed to compare means between the 3 study groups. ANCOVA was used to further delineate determinants of EMT. CV risk factors were regressed on EMT and other covariates in general linear models. Results: Mean EMT was lower in L (0.86±.28) compared to the O (0.98±.24) and T (1.00±.28) subjects, p&lt;0.05. Age and BMIz at baseline and change in glucose were determinants of EMT, while differences between study groups were no longer significant. EMT predicted higher CRP, but, significance was lost after adjustment for follow-up BMIz. EMT predicted higher Beta and Peterson’s which persisted after adjustment for BMI, glucose, and CRP. Conclusion: Adiposity and poor glucose control may lead to increased perivascular fat. Thicker EMT may lead to increased carotid stiffness, a risk factor for CV events. Public health measures to reduce obesity and glycemic-related arterial changes are needed to prevent future heart attack and stroke.
Pemphigus with features of both vulgaris and foliaceus variants, associated with antibodies to 160 and 130 kDa antigens
Authors: None Izumi, None Seishima, None Satoh, None Ito, None Kamiya, None Kitajima
Journal: British Journal of Dermatology (1998)

We report an unusual variant of pemphigus in a 44-year-old man. He presented with scaly and crusted erosions associated with pruritic vesicles and erythema mainly on the chest, abdomen, back and face. Histology showed acantholysis with neutrophilic spongiosis in the granular layer and subcorneal region of the epidermis. Intercellular IgG in the epidermis was positive on direct immunofluorescence. Indirect immunofluorescence showed intercellular antibodies at a titre of 1 : 2 in the suprabasal epidermis. Circulating autoantibodies to 130 kDa and 160 kDa antigens were detected in the patient's serum by immunoblot analysis using epidermal extracts. These two antibodies eluted from individual nitrocellulose membranes reacted with the intercellular space in the epidermis on indirect immunofluorescence. This observation suggests that these antibodies correspond to desmogleins 3 and 1, respectively. The clinical symptoms almost completely disappeared after 28 days treatment with oral prednisolone (30 mg/day), leaving brown pigmented flecks on the lesional sites. These findings suggest that this patient's pemphigus has features of both the vulgaris and foliaceus variants, with antibodies against desmogleins 3 and 1.